Developer docs
API playgroundTry for free, no card

Search company profiles

DT MedTech

Full company profile

uuid002tks6

Namestring
DT MedTech
Legal namestring
DT MedTech, LLC
Websiteurl
dtmedtech.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

DT MedTech, LLC is a privately held medical device company headquartered in McMinnville, Tennessee, that develops and distributes lower extremity orthopedic products, principally the Hintermann Series total ankle replacement (TAR) systems. Founded in 2016 to commercialize the intellectual property of Prof. Beat Hintermann (Chairman of Orthopaedics and Traumatology at Kantonsspital Baselland, Switzerland), the company's core portfolio consists of the H3—a non-constrained, mobile-bearing, three-component TAR system (cobalt chromium tibial component, anatomically shaped talar component, UHMWPE mobile bearing insert) with plasma-spray titanium and hydroxyapatite coatings for bone ingrowth—and the H2, a semi-constrained two-component TAR system with anterior/neutral/posterior PE inlay offsets. Both systems use a single instrument set and surgical approach, enabling surgeons to select mobile-bearing or semi-constrained options intraoperatively. The portfolio also includes the Kalix II subtalar arthroereisis implant for flatfoot deformities. Clinical evidence cited includes 88% survivorship at seven years and 95.9% patient satisfaction at five years for the H3, with 20,000+ H3 implantations globally since 2000 and a published 684-patient survivorship analysis.

The company sells its products through a distribution-based go-to-market model with 50+ US distributors, 25+ international distribution partners, and 300+ field representatives, supported by logistics partners HealthLink Europe International (US) and HealthLink Europe BV (Netherlands). End customers are orthopedic foot and ankle surgeons and the hospitals/surgical centers performing TAR procedures, with marketing concentrated on clinical publications, surgeon training programs, and peer-to-peer education rather than consumer advertising. Regulatory milestones include CE marking (August 2016), FDA 510(k) clearance for H2 (November 2017), and FDA Premarket Approval for H3 (June 2019); products are registered in 30+ countries. Pricing is not publicly disclosed and is negotiated through surgeon/hospital procurement channels.

Since July 2020, DT MedTech has operated as a wholly owned subsidiary of Vilex, LLC, a member of the Squadron Capital family of businesses, with international operations conducted through DT MedTech International Limited (Ireland). The Vilex acquisition integrated the Hintermann Series with Vilex's US sales organization, expanding US commercial coverage. Revenue is generated through hardware sales of implants and instrumentation, and the company maintains its own quality system for manufacturing.

Short descriptiontext

DT MedTech, LLC develops and distributes the Hintermann Series total ankle replacement systems (H2 semi-constrained and H3 mobile-bearing) and the Kalix II subtalar arthroereisis implant, serving orthopedic foot and ankle surgeons and hospitals across 30+ countries through a distributor-based model.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
Headquarters's-hertogenbosch, Netherlands
HQ citystring
's-hertogenbosch
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
total ankle replacement, orthopedic implants, lower extremity surgery, ankle arthroplasty, subtalar arthroereisis
Industry3 codes
PRIMARYHLAHAEAA
Orthopedic Joint Reconstruction Implants (Hip/Knee/Shoulder/Elbow/Ankle)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAKALAG
Foot & Ankle
SECONDARYHLAHADAA
Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
NAICS code2 codes
  • Surgical Appliance and Supplies Manufacturing339113
  • Surgical and Medical Instrument Manufacturing339112
SIC code2 codes
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
  • Surgical & Medical Instruments & Apparatus3841
Product category
Orthopedic Implants
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales
TypeHardware Sales
Description

DT MedTech generates revenue through the sale of total ankle replacement implants and instrumentation. The company sells directly through its US distribution network and internationally through HealthLink Europe BV and other distributors. Products include Hintermann Series H2 and H3 total ankle replacement systems, along with revision components.

dtmedtech.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Operations, Technology or R&D, Marketing or Sales, Personnel, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Hintermann Series H2
Description

Two-piece, semi-constrained total ankle replacement system indicated for cemented use in the US and non-cemented use outside the US. Used for primary ankle replacement and revision surgery.

dtmedtech.com
+2 more records
Core offering1 text field

DT MedTech manufactures and distributes the Hintermann Series total ankle replacement (TAR) systems, including the H3 mobile-bearing three-component system and the H2 semi-constrained two-component system, along with the Kalix II subtalar arthroereisis implant. Both TAR systems share a single surgical instrument set, enabling orthopedic foot and ankle surgeons to choose the optimal implant design intraoperatively for primary or revision ankle replacement procedures. The company sells directly to hospitals and surgical centers through a network of distributors in the US and internationally, with FDA PMA approval (H3) and 510(k) clearance (H2) in the United States and CE marking across Europe and other international markets.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 88% survivorship at 7 years post-implantation for H3 system
+3 more records
Product overview1 text field

DT MedTech, LLC offers a portfolio of lower extremity medical devices, primarily the Hintermann Series Total Ankle Replacement Systems. The core products are the Hintermann Series H3® (a three-piece, mobile-bearing, non-constrained TAR system) and the Hintermann Series H2® (a two-piece, semi-constrained TAR system). Both systems utilize a single instrument set and surgical approach, allowing surgeons to choose between mobile-bearing and semi-constrained options for primary and revision total ankle replacement procedures. The portfolio also includes the Kalix® II subtalar arthroereisis implant for treating flatfoot deformities. All products were developed by Prof. Beat Hintermann and the company operates under Vilex, LLC as a wholly owned subsidiary following the 2020 acquisition.

Product and service3 records
1Hintermann Series H3 Total Ankle Replacement System
CategoryTotal Ankle Replacement System
Description

A three-component, non-constrained, mobile-bearing total ankle replacement system consisting of a cobalt chromium tibial component, anatomically-shaped talar component, and ultra-high molecular weight polyethylene (UHMWPE) mobile bearing insert. Indicated for primary osteoarthritis, post-traumatic osteoarthritis, and arthritis secondary to inflammatory disease. Features Plasma Spray Titanium and Hydroxyapatite coating for non-cemented use and optimal bone ingrowth. Available in seven sizes with PE inlay in four thicknesses. Used by orthopedic foot and ankle surgeons performing primary TAR procedures.

2Hintermann Series H2 Total Ankle Replacement System
CategoryTotal Ankle Replacement System
Description

A two-component, semi-constrained total ankle replacement system consisting of a talar component, tibial assembly component (tibial slide and tray), and PE inlay assembly component. Designed for cemented use in the US and non-cemented use outside the US. Indicated for primary or revision surgery of ankle joints damaged by systemic, primary, or secondary arthritis. Features anterior, neutral, and posterior offset options for alignment reconstruction. Used by orthopedic foot and ankle surgeons who prefer a semi-constrained design for patients with ankle instability.

3Kalix II Subtalar Arthroereisis Implant
CategorySubtalar Arthroereisis Implant
Description

A subtalar arthroereisis implant used to treat flatfoot deformities. Part of the Hintermann Series lower extremity product portfolio acquired by DT MedTech. Used by orthopedic foot and ankle surgeons for pediatric and adult flatfoot correction procedures.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-07-23
Description

Vilex LLC, a member of Squadron Capital family of businesses, acquired DT MedTech LLC in July 2020. DT MedTech became a wholly owned subsidiary of Vilex. The acquisition combined Vilex's US market presence with DT MedTech's globally-renowned Hintermann Series product portfolio, creating a global leader in lower extremity surgical solutions. Vilex now supports Hintermann Series products through its sales organization.

2HealthLink Europe BV
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

HealthLink Europe BV handles logistics and distribution for DT MedTech products outside the US from their Netherlands location (De Tweeling 20-22, 5215 MC's-Hertogenbosch). Handles majority of logistics for products in approved countries including all EU markets.

dtmedtech.com
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

HealthLink Europe International handles US logistics and distribution from its US headquarters in Raleigh, NC. Handles DT MedTech product distribution within the United States, including H2 and H3 sales and distribution.

4Professor Beat Hintermann
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Prof. Beat Hintermann, Chairman of the Clinic for Orthopaedics and Traumatology at Kantonsspital Baselland in Liestal, Switzerland, developed the Hintermann Series H3 and H2 TAR systems. He continues as a key collaborator and inventor, with over 20 years of clinical experience. He remains involved in product development and surgeon training.

dtmedtech.com
Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

M Squared Associates served as advisors to DT MedTech in regulatory processes, including FDA PMA approval for H3 and 510(k) clearance for H2.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Competitive moat5 records

Each record includes

Type, Details

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

DT MedTech

Orthopedic Implantsdtmedtech.com

DT MedTech, LLC develops and distributes the Hintermann Series total ankle replacement systems (H2 semi-constrained and H3 mobile-bearing) and the Kalix II subtalar arthroereisis implant, serving orthopedic foot and ankle surgeons and hospitals across 30+ countries through a distributor-based model.

What DT MedTech does

DT MedTech, LLC is a privately held medical device company headquartered in McMinnville, Tennessee, that develops and distributes lower extremity orthopedic products, principally the Hintermann Series total ankle replacement (TAR) systems. Founded in 2016 to commercialize the intellectual property of Prof. Beat Hintermann (Chairman of Orthopaedics and Traumatology at Kantonsspital Baselland, Switzerland), the company's core portfolio consists of the H3—a non-constrained, mobile-bearing, three-component TAR system (cobalt chromium tibial component, anatomically shaped talar component, UHMWPE mobile bearing insert) with plasma-spray titanium and hydroxyapatite coatings for bone ingrowth—and the H2, a semi-constrained two-component TAR system with anterior/neutral/posterior PE inlay offsets. Both systems use a single instrument set and surgical approach, enabling surgeons to select mobile-bearing or semi-constrained options intraoperatively. The portfolio also includes the Kalix II subtalar arthroereisis implant for flatfoot deformities. Clinical evidence cited includes 88% survivorship at seven years and 95.9% patient satisfaction at five years for the H3, with 20,000+ H3 implantations globally since 2000 and a published 684-patient survivorship analysis.

The company sells its products through a distribution-based go-to-market model with 50+ US distributors, 25+ international distribution partners, and 300+ field representatives, supported by logistics partners HealthLink Europe International (US) and HealthLink Europe BV (Netherlands). End customers are orthopedic foot and ankle surgeons and the hospitals/surgical centers performing TAR procedures, with marketing concentrated on clinical publications, surgeon training programs, and peer-to-peer education rather than consumer advertising. Regulatory milestones include CE marking (August 2016), FDA 510(k) clearance for H2 (November 2017), and FDA Premarket Approval for H3 (June 2019); products are registered in 30+ countries. Pricing is not publicly disclosed and is negotiated through surgeon/hospital procurement channels.

Since July 2020, DT MedTech has operated as a wholly owned subsidiary of Vilex, LLC, a member of the Squadron Capital family of businesses, with international operations conducted through DT MedTech International Limited (Ireland). The Vilex acquisition integrated the Hintermann Series with Vilex's US sales organization, expanding US commercial coverage. Revenue is generated through hardware sales of implants and instrumentation, and the company maintains its own quality system for manufacturing.

DT MedTech firmographics

Firmographics
Name
DT MedTech
Legal name
DT MedTech, LLC
Website
https://dtmedtech.com
Company type
Private
Founded year
2016
Operating status
Acquired
Headcount range
11–50 employees
Short description
DT MedTech, LLC develops and distributes the Hintermann Series total ankle replacement systems (H2 semi-constrained and H3 mobile-bearing) and the Kalix II subtalar arthroereisis implant, serving orthopedic foot and ankle surgeons and hospitals across 30+ countries through a distributor-based model.
Ownership category
akta.pro rank

DT MedTech industry classification

Industry
Product category
Orthopedic Implants
NAICS
Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112)
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAEAA
Orthopedic Joint Reconstruction Implants (Hip/Knee/Shoulder/Elbow/Ankle)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAKALAG
Foot & Ankle
SECONDARYHLAHADAA
Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment

Keywords

  • Total ankle replacement
  • Orthopedic implants
  • Lower extremity surgery
  • Ankle arthroplasty
  • Subtalar arthroereisis

Where DT MedTech is headquartered

Location

Headquarters

HQ city
's-hertogenbosch
HQ country
Netherlands
HQ region
Europe

Offices3 records

Markets served

DT MedTech business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Technology or R&D, Marketing or Sales, Personnel, Infrastructure

Revenue model

  1. Medical Device Sales: DT MedTech generates revenue through the sale of total ankle replacement implants and instrumentation. The company sells directly through its US distribution network and internationally through HealthLink Europe BV and other distributors. Products include Hintermann Series H2 and H3 total ankle replacement systems, along with revision components.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

DT MedTech product offering

Product offering

Core offering

DT MedTech manufactures and distributes the Hintermann Series total ankle replacement (TAR) systems, including the H3 mobile-bearing three-component system and the H2 semi-constrained two-component system, along with the Kalix II subtalar arthroereisis implant. Both TAR systems share a single surgical instrument set, enabling orthopedic foot and ankle surgeons to choose the optimal implant design intraoperatively for primary or revision ankle replacement procedures. The company sells directly to hospitals and surgical centers through a network of distributors in the US and internationally, with FDA PMA approval (H3) and 510(k) clearance (H2) in the United States and CE marking across Europe and other international markets.

Product overview

DT MedTech, LLC offers a portfolio of lower extremity medical devices, primarily the Hintermann Series Total Ankle Replacement Systems. The core products are the Hintermann Series H3® (a three-piece, mobile-bearing, non-constrained TAR system) and the Hintermann Series H2® (a two-piece, semi-constrained TAR system). Both systems utilize a single instrument set and surgical approach, allowing surgeons to choose between mobile-bearing and semi-constrained options for primary and revision total ankle replacement procedures. The portfolio also includes the Kalix® II subtalar arthroereisis implant for treating flatfoot deformities. All products were developed by Prof. Beat Hintermann and the company operates under Vilex, LLC as a wholly owned subsidiary following the 2020 acquisition.

Differentiator

Problem solved

Functional benefit

Brands

  • Hintermann Series H2: Two-piece, semi-constrained total ankle replacement system indicated for cemented use in the US and non-cemented use outside the US. Used for primary ankle replacement and revision surgery.
  • Hintermann Series H3
  • Kalix II

Products and services

  • Hintermann Series H3 Total Ankle Replacement System A three-component, non-constrained, mobile-bearing total ankle replacement system consisting of a cobalt chromium tibial component, anatomically-shaped talar component, and ultra-high molecular weight polyethylene (UHMWPE) mobile bearing insert. Indicated for primary osteoarthritis, post-traumatic osteoarthritis, and arthritis secondary to inflammatory disease. Features Plasma Spray Titanium and Hydroxyapatite coating for non-cemented use and optimal bone ingrowth. Available in seven sizes with PE inlay in four thicknesses. Used by orthopedic foot and ankle surgeons performing primary TAR procedures.
  • Hintermann Series H2 Total Ankle Replacement System A two-component, semi-constrained total ankle replacement system consisting of a talar component, tibial assembly component (tibial slide and tray), and PE inlay assembly component. Designed for cemented use in the US and non-cemented use outside the US. Indicated for primary or revision surgery of ankle joints damaged by systemic, primary, or secondary arthritis. Features anterior, neutral, and posterior offset options for alignment reconstruction. Used by orthopedic foot and ankle surgeons who prefer a semi-constrained design for patients with ankle instability.
  • Kalix II Subtalar Arthroereisis Implant A subtalar arthroereisis implant used to treat flatfoot deformities. Part of the Hintermann Series lower extremity product portfolio acquired by DT MedTech. Used by orthopedic foot and ankle surgeons for pediatric and adult flatfoot correction procedures.

Quantifiable outcome

  • 88% survivorship at 7 years post-implantation for H3 system
  • +3 more outcomes

Companies that use DT MedTech

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles1 record

DT MedTech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

DT MedTech partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • Vilex LLCcoreStrategic or Co-development Partner · 23 July 2020Vilex LLC, a member of Squadron Capital family of businesses, acquired DT MedTech LLC in July 2020. DT MedTech became a wholly owned subsidiary of Vilex. The acquisition combined Vilex's US market presence with DT MedTech's globally-renowned Hintermann Series product portfolio, creating a global leader in lower extremity surgical solutions. Vilex now supports Hintermann Series products through its sales organization.
  • HealthLink Europe BVcoreChannel Partner/ Reseller/ DistributorHealthLink Europe BV handles logistics and distribution for DT MedTech products outside the US from their Netherlands location (De Tweeling 20-22, 5215 MC's-Hertogenbosch). Handles majority of logistics for products in approved countries including all EU markets.
  • HealthLink Europe InternationalcoreChannel Partner/ Reseller/ DistributorHealthLink Europe International handles US logistics and distribution from its US headquarters in Raleigh, NC. Handles DT MedTech product distribution within the United States, including H2 and H3 sales and distribution.
  • Professor Beat HintermanncoreStrategic or Co-development PartnerProf. Beat Hintermann, Chairman of the Clinic for Orthopaedics and Traumatology at Kantonsspital Baselland in Liestal, Switzerland, developed the Hintermann Series H3 and H2 TAR systems. He continues as a key collaborator and inventor, with over 20 years of clinical experience. He remains involved in product development and surgeon training.
  • M Squared AssociatesminorImplementation/ SI/ Consulting PartnerM Squared Associates served as advisors to DT MedTech in regulatory processes, including FDA PMA approval for H3 and 510(k) clearance for H2.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

DT MedTech competitors and assessment

Company assessment

Market position

Competitive moat5 records

Key highlights6 records

Customer concentration

DT MedTech social profiles

Digital presence

DT MedTech compliance and trust

Trust signal

Compliance2 records

DT MedTech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

DT MedTech leadership team

Management profile

Number of profiles

Profiles1 record

DT MedTech subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

DT MedTech funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

DT MedTech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DT MedTech

What does DT MedTech do?

DT MedTech manufactures and distributes the Hintermann Series total ankle replacement (TAR) systems, including the H3 mobile-bearing three-component system and the H2 semi-constrained two-component system, along with the Kalix II subtalar arthroereisis implant. Both TAR systems share a single surgical instrument set, enabling orthopedic foot and ankle surgeons to choose the optimal implant design intraoperatively for primary or revision ankle replacement procedures. The company sells directly to hospitals and surgical centers through a network of distributors in the US and internationally, with FDA PMA approval (H3) and 510(k) clearance (H2) in the United States and CE marking across Europe and other international markets.

Is DT MedTech a public or private company?

DT MedTech is a private company. It is classified as private equity controlled and is currently acquired.

When was DT MedTech founded?

DT MedTech was founded in 2016. It employs 11 to 50 people.

Where is DT MedTech based?

DT MedTech is headquartered in 's-hertogenbosch, Netherlands, in the Europe region.

How does DT MedTech make money?

One revenue line is on record: medical Device Sales.

Does DT MedTech have an API?

No public API is recorded for DT MedTech.

What industry is DT MedTech in?

DT MedTech's product category is Orthopedic Implants. Its primary akta.pro industry code is HLAHAEAA, Orthopedic Joint Reconstruction Implants (Hip/Knee/Shoulder/Elbow/Ankle), with a secondary code of HLAKALAG, Foot & Ankle. Its NAICS code is 339113 and its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireVilex Acquires DT MedTech and the Hintermann Series System™ Total Ankle ProsthesesVilex, LLC has completed the acquisition of DT MedTech, LLC, including the Hintermann Series System™ Total Ankle Replacement product portfolio developed by Professor Beat Hintermann. The acquired products include the FDA-cleared H2 (2-piece, semi-constrained) and FDA-approved H3 (3-piece, mobile-bearing) TAR prostheses, which are sold in over 30 countries and have been clinically time-tested globally for over 20 years. DT MedTech becomes a wholly owned subsidiary of Vilex, with the combined entity now offering over 50 US distributors and 25+ international distribution partners comprising more than 300 field representatives, positioning Vilex as a global leader in lower extremity surgical solutions.PR NewswireDT MedTech Announces the First US Implantation of the Hintermann Series H3™ Total Ankle Replacement System at the Lakewood Ranch Medical CenterDT MedTech announced the successful first US implantation of its Hintermann Series H3™ Total Ankle Replacement System at Lakewood Ranch Medical Center in Sarasota, Florida, performed by Dr. James Cottom. The device received FDA PMA approval in June 2019, making this the first US surgery using the non-constrained total ankle replacement system developed by Dr. Beat Hintermann. The company expects a full US product launch of the H3 in December 2019.PR NewswireLa FDA otorga una autorización previa a la comercialización para el sistema Hintermann Serie H3™ de DT MedTechDT MedTech, LLC received pre-market approval (PMA) from the US FDA for the Hintermann Series H3™ total ankle replacement system, a three-component mobile-bearing implant indicated for replacing arthritic ankle joints. The H3 was developed by Dr. Beat Hintermann and has been implanted in over 20,000 patients outside the United States since its first launch in May 2000. Clinical data cited in the FDA summary showed 95.9% of H3 patients reported being moderately to very satisfied five years post-implantation, with an 88% survival rate at 7 years.PR NewswireLa FDA octroie une approbation préalable à la commercialisation au système de remplacement complet de la cheville Hintermann série H3™ de DT MedTechDT MedTech, LLC received FDA Premarket Approval (PMA) for its Hintermann Series H3™ total ankle replacement system in the United States on June 6, 2019. The H3 system, developed by Swiss surgeon Professor Beat Hintermann, has been implanted in over 20,000 patients outside the US since May 2000, with clinical data showing 95.9% patient satisfaction at five years and an 88% survival rate at seven years. DT MedTech will now be able to commercialize the product in the US market alongside its existing H2 cementless system.PR NewswireFDA erteilt „Premarket Approval" für Hintermann Series H3™ Total Ankle Replacement System von DT MedTechDT MedTech, LLC announced that its Hintermann Series H3™ Total Ankle Replacement system received Premarket Approval (PMA) from the U.S. Food and Drug Administration on June 6, 2019, clearing the device for use in the United States. The H3 is a three-part, non-cemented mobile-bearing implant designed to replace painful, arthritic ankles caused by osteoarthritis, post-traumatic osteoarthritis, or inflammatory disease, and has been used in over 20,000 patients outside the U.S. since May 2000. FDA clinical data cited in the approval showed that 95.9% of H3 patients were moderately to very satisfied five years after implantation, with an 88% survival rate at seven years.PR NewswireFDA Premarket Approval Granted for DT MedTech's Hintermann Series H3™ Total Ankle Replacement SystemDT MedTech announced that its Hintermann Series H3 Total Ankle Replacement System has received premarket approval from the U.S. Food and Drug Administration. The device, which has been implanted in over 20,000 patients outside the U.S., is indicated for replacing painful arthritic ankle joints. This approval allows DT MedTech to market the three-piece mobile-bearing implant to American surgeons.PR NewswireDT MedTech anuncia exitosos implantes de la nueva prótesis para reemplazo total de tobillo, Hintermann Series H2™DT MedTech announced that Professor Beat Hintermann successfully implanted five H2 total ankle replacement devices in patients in Liestal, Switzerland. The company plans to launch the device outside the US in early February and in the US by late March, with distribution handled by HealthLink Europe International in the US and HealthLink Europe BV internationally.PR NewswireDT MedTech annonce le succès des implantations de la nouvelle prothèse de remplacement total de la cheville Hintermann Series H2™DT MedTech announced the successful implantation of its new Hintermann Series H2™ total ankle replacement prosthesis, with Prof. Hintermann reporting that patients were able to bear weight just 24 hours after surgery. The company plans a limited market launch beginning in early February outside the United States and in late March in the US, with distribution handled by HealthLink Europe International for the US and Europe BV for European markets. DT MedTech CEO David Reicher expressed optimism for a "very successful launch" following focused training and sales efforts across global markets.PR NewswireDT MedTech anuncia la implantación exitosa de la prótesis de artroplastia total de tobillo del nuevo Hintermann Series H2™DT MedTech, LLC has successfully implanted five Hintermann Series H2™ total ankle replacement devices in patients in Liestal, Switzerland, as announced on February 8, 2018. The H2 system is indicated for use as an uncemented implant outside the United States and as a cemented implant within the country, aimed at replacing arthritic ankle joints. The company plans limited release of the H2 system starting in February outside the U.S. and anticipates a broader launch by March in the U.S.PR NewswireDT MedTech meldet erfolgreiche Implantationen der neuen Sprunggelenkprothese Hintermann Series H2™DT MedTech announced successful implantation of the Hintermann Series H2™ total ankle replacement system in five patients in Liestal, Switzerland, performed by Prof. Beat Hintermann. The H2 system is a semi-rigid prosthesis intended for cemented use in the United States and uncemented use outside the US, targeting patients with painful arthritic ankles from osteoarthritis or inflammatory diseases. The company plans limited market release starting early February outside the US and late March in the US, with distribution managed through HealthLink Europe partners in Raleigh, NC and the Netherlands.